BGB-A317-314

Recruiting

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Beigene Study ID info

BGB-A317-314

ClinicalTrials.gov ID info

China Drug Trials ID info

CTR20201517

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents